Journal of Thrombosis and Thrombolysis

, Volume 28, Issue 4, pp 436–443

Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients

  • Joan-Carles Trullas-Vila
  • Josep Bisbe-Company
  • Adriana Freitas-Ramírez
  • Silvia Soler-Simon
  • Vicenta Bisbe-Company
  • Josep-Maria Roncero-Vidal
  • Rosa Gispert-Magarolas
Article

DOI: 10.1007/s11239-009-0311-9

Cite this article as:
Trullas-Vila, JC., Bisbe-Company, J., Freitas-Ramírez, A. et al. J Thromb Thrombolysis (2009) 28: 436. doi:10.1007/s11239-009-0311-9

Abstract

Objective To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997–2007). Results Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region’s population). The total follow-up was 5,462 patients-years. Median age was 74 years. INR therapeutic range was 2.0–3.0 in 82.5%. Atrial fibrillation (AF) was the most frequent indication (73%). Incidence of hemorrhagic and thrombotic events was 2.27 and 0.2/100 patients-year, respectively. Gastrointestinal tract was the most frequent site of bleeding. In multivariate analysis, patients with AF and prosthetic heart valves (PHV) had increased risk of bleeding (OR 2.1 and 4.8, respectively). Age and therapeutic ranges of INR were not associated with increased risk of bleeding. Conclusions 2% of our population is receiving acenocoumarol. Incidence of hemorrhagic and thrombotic events was low. Patients with AF and PHV had increased risk of bleeding.

Keywords

Anticoagulant drugsAcenocoumarolHemorrhageBleeding

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Joan-Carles Trullas-Vila
    • 1
  • Josep Bisbe-Company
    • 1
  • Adriana Freitas-Ramírez
    • 2
  • Silvia Soler-Simon
    • 1
  • Vicenta Bisbe-Company
    • 1
  • Josep-Maria Roncero-Vidal
    • 3
  • Rosa Gispert-Magarolas
    • 2
  1. 1.Internal Medicine ServiceHospital Sant JaumeOlot, GironaSpain
  2. 2.Departament de SalutGeneralitat de Catalunya, Servei d’Informació i EstudisBarcelonaSpain
  3. 3.Hematology ServiceDr. Josep Trueta Universitary HospitalGironaSpain